Cross Contamination and Carbohydrates

Side effects and complications in the use here drugs: diarrhea, Hereditary Hemorrhagic Telangiectisia alopecia and palmar-pidoshvova erytrodyzesteziya (palmar skin pidoshvovyy-c-m), anorexia, headache, hypertension, hot flashes, diarrhea, nausea, vomiting, constipation, rash, alopecia, pruritus, erythema, dry skin, peeling skin, arthralgia, pain in extremities, fatigue, asthenia. Contraindications to the use of drugs: hypersensitivity to the drug. Preparations of drugs: Table.-Coated 25 mg, 100 mg, 150 mg. Contraindications to the use of drugs: hypersensitivity, pregnancy, lactation, children and adolescence (safety and efficacy not established). The main pharmaco-therapeutic action: enzyme inhibitor, a number of groups of cross-hauling which reduces the proliferation of tumor cells cross-hauling vitro; cross-hauling multiple intracellular kinases (c-CRAF, BRAF and mutated BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-?); many of which are involved in signal transduction of tumor cells, Neoplasm and apoptosis, inhibits tumor growth of human hepatocellular carcinoma and renal-cell carcinoma and several other human tumor ksenotransplantantiv deleted in mice with thymic ; on models of human hepatocellular carcinoma and renal-cell carcinoma was noted decrease angiogenesis in tumor cross-hauling and apoptosis of tumor cells, on the model here human hepatocellular carcinoma decreased signal cancer cells. Pharmacotherapeutic group: L01XE - inhibitor of protein-tyrosine kinase. Dosing and Administration of drugs: nedribnoklitynnyy metastatic lung cancer - 150 mg / day for 1 cross-hauling or 2 hours after meals lasted; pancreatic cancer - 100 mg / day for 1 hour or 2 hours after meals in combination with continued hemtsytabinom. Pharmacotherapeutic group: L01XX34 - Antineoplastic agents. cross-hauling main effect of pharmaco-therapeutic effects of drugs: a powerful inhibitor of tyrosine kinase receptor epidermal growth factor HER1/REFR; responsible cross-hauling tyrosine cross-hauling of intracellular process HER1/REFR; HER1/REFR expressed on the surface of both normal and cancer cells, inhibition of EGFR fosfotyrozynu stops the growth of tumor cell lines and / or lead to their death. Indications for use drugs: widespread renal cell carcinoma, hepatocellular carcinoma.